Insmed Inc (INSM)vsPuma Biotechnology Inc (PBYI)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PBYI
Puma Biotechnology Inc
$6.33
+1.12%
HEALTHCARE · Cap: $317.98M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 166% more annual revenue ($606.42M vs $228.37M). PBYI leads profitability with a 13.6% profit margin vs -2.1%. PBYI appears more attractively valued with a PEG of 0.03. PBYI earns a higher WallStSmart Score of 71/100 (B).
INSM
Hold39
out of 100
Grade: F
PBYI
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-60.0%
Fair Value
$4.15
Current Price
$6.33
$2.18 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Growing faster than its price suggests
Attractively priced relative to earnings
Every $100 of equity generates 28 in profit
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Revenue surging 27.7% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
Earnings declined 34.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, P/E Ratio, Return on Equity. Revenue growth of 27.7% demonstrates continued momentum. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, EPS Growth.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PBYI is a growth play — different risk/reward profiles.
PBYI carries more volatility with a beta of 1.27 — expect wider price swings.
PBYI is growing revenue faster at 27.7% — sustainability is the question.
PBYI generates stronger free cash flow (14M), providing more financial flexibility.
Bottom Line
PBYI scores higher overall (71/100 vs 39/100) and 27.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?